Latest News & Successes

Parsity Group successfully appoint Christoph Stoller as President & Business Head Europe for Glenmark Pharmaceuticals.

London, United Kingdom: Parsity Group are pleased to announce their successful partnership with Glenmark Pharmaceuticals to secure Christoph Stoller as President & Business Head Europe, effective 15th November 2021.

Glenmark Pharmaceuticals recently announced the expansion of its executive team with the appointment of Christoph Stoller as its President and Business Head Europe

A mandated pan-Europe executive search was undertaken by Parsity Group in preparation for what is set to be a transformative period for Glenmark Pharmaceuticals in the region. Well respected pharma leader, Christoph Stoller, arrives from Teva Pharmaceuticals where he was most recently Region Cluster Head Germany & Austria. At Glenmark Pharmaceuticals he will spear head the continued expansion of the company’s operations in Europe.

Having started on the 15th November 2021, he will be based in Germany. Mr Stoller brings an extensiveand relevant track record within the pharmaceutical sector going back over 20 years, which will prove invaluable as Glenmark Pharmaceuticals ramps up it’s growth from both a portfolio and geographical perspective.

President, Business Head Europe, Christoph Stoller commented:

“I enjoyed the experience working with Parsity Group. Dan Nathan is a very experienced executive head-hunter who has successfully guided me through the entire process, from the first contact until contract signature. Hands-on and highly supportive. I would always work with Parsity Group again”.

About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited (Glenmark) is a global research-led pharmaceutical companywith presence across generics, specialty and OTC businesses and with operations in over 50countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology.It ranks among the world’s top 50 Generics and Biosimilars companies (Top 50 Company Rankings,2020, from Informa’s Generics Bulletin). The company has been listed on the Dow JonesSustainability Index (DJSI), under the category of emerging markets for the third consecutive year ina row. DJSI is one of the world’s most respected and widely accepted sustainability benchmarksglobally with only the top ranked companies in terms of Corporate Sustainability within eachindustry being featured in the index. For more information, visit , www.glenmarkpharma.com

© Copyright 2022 Parsity Group